Imatinib intermidiate
106261-49-8
152460-10-1
152460-09-8
Gefitinib intermidiate
179688-53-0
184475-70-5
Oseltamivir Intermediate
651324-08-2
204254-96-6
Ebastine Intermediate
143878-20-0
Aripiprazole Intermediate
129722-34-5
22246-18-0
119532-26-2
NEWS
Site relocation notice
DATE: 2018-11-07 AUTHOR:

In order to speed up the transformation and upgrading of the company, improve the level of enterprise automation, meet the needs of advanced production technology and equipment level, and realize intelligent and green development, the company has invested 210 million yuan in the new project of Mamu-Nanfeng Provincial High-tech Industrial Park to built new high-standard high-start production base by increasing floor area of 72 acres, and new construction area of 40,000 square meters. At present, the infrastructure is basically completed, and the equipment installation is expected to be completed by the end of 2018, and put into use in early 2019. Relying on the unique platform advantages and geographical advantages of the park, Foster will further enhance the market competitiveness of our products and promote the sustainable development of the enterprise.

Copyright(C)2011 Hangzhou FST pharmaceutical Co., Ltd. All Rights Reserved. Supported by ChemNet ChinaChemNet Toocle
浙ICP备05006485号-1